Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 15/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541408 | 0.83 | CA9 (0.53) | CA9CA2CA12ELANEKMT2A | |
| SCHEMBL9503181 | 0.82 | CA9 (0.51) | CA9CA2CA12ELANEKMT2A | |
| SCHEMBL7462238 | 0.79 | CA9 (0.49) | CA9CA2CA12ELANEKMT2A | |
| SCHEMBL7307926 | 0.78 | CA12 (0.48) | CA9CA2CA12ELANEKMT2A | |
| SCHEMBL8550846 | 0.77 | CA9 (0.38) | CA9CA2CA12ELANEKMT2A | |
| SCHEMBL16126846 | 0.76 | CA9 (0.37) | CA9CA2CA12KMT2ACA1 | |
| SCHEMBL7335719 | 0.76 | PTGDR2 (0.44) | CA9CA2CA12CA1 | |
| SCHEMBL1369709 | 0.76 | PTGDR2 (0.42) | CA9CA2CA12KMT2ATDP1 | |
| SCHEMBL30339085 | 0.75 | CA9 (1.00) | CA9CA2CA12ELANELMNA | |
| SCHEMBL107126 | 0.75 | CA9 (1.00) | CA9CA2CA12ELANELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI INDUSTRIES LTD. (IN) | 2020-09-10 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| EP-0752990-B1 | BENZISOTHIAZOLES DERIVATIVES AS INHIBITORS OF 5-LIPOXYGENASE BIOSYNTHESIS | PFIZER (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0232364-B1 | SUBSTITUTED SACCHARIN COMPOUNDS AND CURABLE COMPOSITIONS CONTAINING SAME | LOCTITE CORP (US) | 1994-02-23 | — | — | EP | disclosed |
| US-5160363-A | For sugarbeets | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-03 | — | — | US | disclosed |
| EP-0422031-A1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0232364-A4 | SUBSTITUTED SACCHARIN COMPOUNDS AND CURABLE COMPOSITIONS CONTAINING SAME. | LOCTITE CORP (US) | 1990-05-14 | — | — | EP | disclosed |
| US-4881968-A | ORTHO-CARBOXYLATE ARYL SUBSTITUTED | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-21 | — | — | US | disclosed |
| WO-1989010921-A1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-16 | — | — | WO | disclosed |
| US-4764239-A | STORAGE STABLE ADHESIVE | LOCTITE CORPORATION (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0232364-A1 | SUBSTITUTED SACCHARIN COMPOUNDS AND CURABLE COMPOSITIONS CONTAINING SAME. | LOCTITE CORP (US) | 1987-08-19 | — | — | EP | disclosed |
| WO-1987000536-A1 | SUBSTITUTED SACCHARIN COMPOUNDS AND CURABLE COMPOSITIONS CONTAINING SAME | LOCTITE CORPORATION (US) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CA9 4030/4885CA2 4417/4885CA12 2765/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | CA9 2593/4885CA2 4006/4885CA12 1936/4885 |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP51A1 | CA9 1733/4885CA2 1601/4885CA12 3721/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | CA9 4129/4885CA2 4288/4885CA12 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.